They work by supporting the bodys natural anabolic (muscle-building) and repair processes
Here's how tesamorelin vs sermorelin and other GHRH peptides compare: GHRH Peptide Comparison Table Property Tesamorelin Sermorelin CJC-1295 (No DAC) CJC-1295 DAC FDA Status FDA Approved (Egrifta) Previously approved, now discontinued Not approved Not approved Amino Acids 44 (modified GHRH) 29 (GHRH 1-29) 29 + modifications 29 + Drug Affinity Complex Half-Life ~26-38 minutes ~10-20 minutes ~30 minutes ~6-8 days Mechanism GHRH receptor agonist GHRH receptor agonist GHRH receptor agonist GHRH receptor agonist (extended) Clinical Trial Data Extensive (Phase 3 completed) Limited (older studies) Limited (Phase 1/2) Limited Primary Research Use Lipodystrophy, NAFLD, body composition GH deficiency research GH axis research Extended GH release research Key Differentiators Tesamorelin's advantages: Only GHRH analog with current FDA approval Extensive Phase 3 clinical trial data Documented efficacy for visceral fat reduction Well-characterized safety profile from prescription use Sermorelin note: Previously FDA-approved (1997) for pediatric growth hormone deficiency but discontinued by manufacturers no longer available as a prescription product in the US
Muscle strength and size Collagen is a type of protein and forms an important component of muscle tissue
How risky is IGF-1 LR3
IGF-1 LR3 and Glucose Metabolism Research In differentiated 3T3-L1 adipocytes, IGF-1 LR3 was used to investigate IGFBP-independent IGF-1R-mediated glucose uptake pathways, with research confirming that its effects on glucose transport are mediated directly through the IGF-1 receptor rather than through IGFBP modulation providing a clean experimental tool for dissecting receptor-specific metabolic signalling
Referenced Citations Svensson, J., et al., The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats
